Navigation Links
MAP Pharmaceuticals to Present Data on LEVADEX™ at the 63rd Annual Meeting of the American Academy of Neurology
Date:2/28/2011

aine in the United States estimated at over $20 billion annually.

About MAP Pharmaceuticals MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.  Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com

Forward-Looking StatementsIn addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the development and regulatory approval process for the Company's LEVADEX product candidate. The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010, available at http://edgar.sec.gov.   CONTACTS: Nicole Foderaro


'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
2. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
3. Cumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
4. Anadys Pharmaceuticals to Report Fourth Quarter and Year-end 2010 Financial Results
5. UCLA and Sound Pharmaceuticals Identify a Key Hearing Regeneration Protein in the Human Inner Ear
6. JHP Pharmaceuticals Enters Another Multi-Year Contract Manufacturing Agreement
7. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Fourth Quarter and Full Year Financial Results
8. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
9. Jazz Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference in New York on March 1
10. Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
11. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014  Grammy Award-winner Bruce Hornsby ... of philanthropists, athletes, actors, and musicians during the 10 ... 19 at the Mandarin Oriental Hotel in ... will honor six individuals who embody the values of ... bestow its highest honor, the Spirit of an Active ...
(Date:10/31/2014)... Oct. 31, 2014 Mast Therapeutics, Inc. (NYSE ... results for the quarter ended September 30, 2014. ... Officer, said:  "The third quarter was productive for Mast. Consistent ... of MST-188 for sickle cell disease is on track ... now have opened 50 study sites in the U.S. ...
(Date:10/31/2014)... 2014 Imago BioSciences, Inc., a biotech ... million Series A financing led by Clarus Ventures ... team of accomplished investment and operating professionals dedicated ... round include Frazier Healthcare, Amgen Ventures, and Merck ... and Frazier Healthcare will join the company,s board ...
Breaking Medicine Technology:10th Anniversary Orthopaedic Foundation Gala Set For Success 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2
... Boston Scientific Corporation (NYSE: BSX ) today announced ... Johnson & Johnson, including the Palmaz-NIR suit. All ... arena. In connection with the settlement, Boston Scientific ... & Johnson. The settlement payment is within Boston ...
... MUMBAI, India, Sept. 29 Pharmaceutical Major, Lupin Ltd. announced ... 43 mg and 130 mg). Lupin acquired the product ... of the U.S. Bankruptcy Court. Antara recorded net sales ... 2008). Lupin paid $ 38.61 million for the product ...
Cached Medicine Technology:Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 2Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 3Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes 4Lupin Expands Branded Play 2Lupin Expands Branded Play 3
(Date:10/31/2014)... 2014 (HealthDay News) -- Access to generic hormone therapy ... stick with their drug treatment, a new study found. ... hormone receptor-positive breast cancer can reduce recurrence by up ... associate professor of epidemiology at Columbia University Medical Center ... release. "However, work by our group and ...
(Date:10/31/2014)... Alan Mozes HealthDay ... In the world of 21st-century medicine, organ transplantation is nothing ... followed by the first liver transplant in 1963 and the ... even managed the transplantation of a patient,s entire face. ... entire human eye. But if one team of U.S. scientists ...
(Date:10/31/2014)... year, people across the United States spend an estimated ... which costs $522 billion, according to new research. ... the time and wages that caregivers give up every ... daily activities. The study authors said the significant financial ... flexibility policies. "Our findings provide a new and ...
(Date:10/30/2014)... Einstein College of Medicine of Yeshiva ... their latest aging research at the Gerontological Society ... include the identification of a genotype that can ... the cellular biology of aging. GSA 2014 will ... "Einstein-Montefiore has distinguished itself in a range of ...
(Date:10/30/2014)... Professor Elly Tanaka and her research group at the ... of Excellence at the TU Dresden (CRTD) demonstrated for ... piece of spinal cord in three dimensions from mouse ... interneurons and dorsal interneurons along the dorsal/ventral axis was ... American journal " Stem Cell Reports " on ...
Breaking Medicine News(10 mins):Health News:Generic Drugs May Help Breast Cancer Patients Stick to Therapy 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:'Informal Care' for Older Americans Tops $500B Annually, Study Finds 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2
... Residents to Eat Right, Move More and ... Milk Their Diets, ST. ... and downs of different fad diets -- which seem to go in and ... out of three Americans -- including twenty-five percent of St.,Louis residents -- remain ...
... The Blue Cross Blue Shield of Michigan,Foundation has won ... Program. The awards, given by the Council on Foundations ... awareness of foundations and corporate giving programs. The,awards will ... Council on,Foundations on Monday, May 5, 2008 in Maryland., ...
... National Academy of Sciences of the United States has ... a member of this prestigious organization of scientists and ... in recognition of his distinguished and continuing achievements in ... has had a key role in a range of ...
... Universitys Lane Center for Computational Biology have discovered ... an automated method for analyzing cell cultures and ... online in the Journal of Machine Learning Research, ... analysis of the microscopic images produced by todays ...
... aims to educate patients on best ways to get condition ... Have asthma or think you might? Then May is the ... breathing disease. , Free asthma screenings are scheduled to be ... of National Asthma and Allergy Awareness Month. The American College ...
... - LMS Medical Systems (TSX: LMZ,AMEX: LMZ), a ... safety software system for obstetrics, today announced that ... the Company,s common,shares from Amex., The decision ... to,streamline operations and control costs in order to ...
Cached Medicine News:Health News:Message to St. Louis, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to St. Louis, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to St. Louis, MO Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:Blue Cross Blue Shield of Michigan Foundation Wins Three National Awards for Communications Excellence from Council on Foundations 2Health News:US honor for professor Jerry Adams 2Health News:Carnegie Mellon technique accelerates biological image analysis 2Health News:Free Asthma Screenings Offered in May 2Health News:LMS to delist from Amex 2
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
Hydrophobic PE filter without self-sealing additives, permits sample recovery after accidental over-pipetting. All filters are sterile (to USP, DAB, Ph.Eur. standards) and PCR clean (free from human ...
Medicine Products: